Cargando…
SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer
Among men, prostate cancer is the second leading cause of cancer-associated mortality, with advanced disease remaining a major clinical challenge. We describe a small molecule, SU086, as a therapeutic strategy for advanced prostate cancer. We demonstrate that SU086 inhibits the growth of prostate ca...
Autores principales: | Rice, Meghan A., Kumar, Vineet, Tailor, Dhanir, Garcia-Marques, Fernando Jose, Hsu, En-Chi, Liu, Shiqin, Bermudez, Abel, Kanchustambham, Vijayalakshmi, Shankar, Vishnu, Inde, Zintis, Alabi, Busola Ruth, Muruganantham, Arvind, Shen, Michelle, Pandrala, Mallesh, Nolley, Rosalie, Aslan, Merve, Ghoochani, Ali, Agarwal, Arushi, Buckup, Mark, Kumar, Manoj, Going, Catherine C., Peehl, Donna M., Dixon, Scott J., Zare, Richard N., Brooks, James D., Pitteri, Sharon J., Malhotra, Sanjay V., Stoyanova, Tanya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861828/ https://www.ncbi.nlm.nih.gov/pubmed/35243415 http://dx.doi.org/10.1016/j.xcrm.2021.100502 |
Ejemplares similares
-
MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer
por: Hsu, En-Chi, et al.
Publicado: (2021) -
Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
por: Hsu, En-Chi, et al.
Publicado: (2020) -
ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype
por: Shen, Michelle, et al.
Publicado: (2023) -
Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer
por: Tailor, Dhanir, et al.
Publicado: (2020) -
Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay
por: Liu, Shiqin, et al.
Publicado: (2021)